Difference between revisions of "Part:BBa K5302002"

 
 
Line 4: Line 4:
  
 
This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like. 8IJZ is an anti-VEGF nanobody, and it has 2 chains.These two chains all show great affinity with VEGF, we plan to use pBBR1MCS-2 plasmid as a backbone and transfer 8IJZ into Escherichia coli Nissle 1917, and finally succeeded in expressing 8IJZ.
 
This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like. 8IJZ is an anti-VEGF nanobody, and it has 2 chains.These two chains all show great affinity with VEGF, we plan to use pBBR1MCS-2 plasmid as a backbone and transfer 8IJZ into Escherichia coli Nissle 1917, and finally succeeded in expressing 8IJZ.
 +
 +
<html>
 +
<div style="text-align:center;">
 +
    <img src="https://static.igem.wiki/teams/5302/images/part-registry-8ijz-1.jpg"
 +
        width="60%" style="display:block; margin:auto;" alt="Jamboree Program" >
 +
    <div style="text-align:center;">
 +
        <caption>
 +
            <b>Figure 1. </b> structure of 8IJZ， from PDB
 +
        </caption>
 +
    </div>
 +
</div>
 +
</html>
 +
 +
<html>
 +
<div style="text-align:center;">
 +
    <img src="https://static.igem.wiki/teams/5302/images/part-registry-8ijz-2.jpg"
 +
        width="60%" style="display:block; margin:auto;" alt="Jamboree Program" >
 +
    <div style="text-align:center;">
 +
        <caption>
 +
            <b>Figure 2. </b> Colony PCR results of pBBR-INP-8IJZ
 +
        </caption>
 +
    </div>
 +
</div>
 +
</html>
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here

Latest revision as of 08:40, 1 October 2024


8IJZ

This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like. 8IJZ is an anti-VEGF nanobody, and it has 2 chains.These two chains all show great affinity with VEGF, we plan to use pBBR1MCS-2 plasmid as a backbone and transfer 8IJZ into Escherichia coli Nissle 1917, and finally succeeded in expressing 8IJZ.

Jamboree Program
Figure 1. structure of 8IJZ， from PDB

Jamboree Program
Figure 2. Colony PCR results of pBBR-INP-8IJZ

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]